1. Home
  2. IMNM vs AMC Comparison

IMNM vs AMC Comparison

Compare IMNM & AMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$23.85

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo AMC Entertainment Holdings Inc.

AMC

AMC Entertainment Holdings Inc.

N/A

Current Price

$2.59

Market Cap

2.4B

ML Signal

N/A

Company Overview

Basic Information
Metric
IMNM
AMC
Founded
2006
1920
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
IMNM
AMC
Price
$23.85
$2.59
Analyst Decision
Strong Buy
Hold
Analyst Count
10
4
Target Price
$32.80
$2.03
AVG Volume (30 Days)
884.8K
19.3M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
$4,848,900,000.00
Revenue This Year
N/A
$11.41
Revenue Next Year
$1,127.34
$5.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.57
52 Week Low
$8.93
$0.93
52 Week High
$30.06
$3.18

Technical Indicators

Market Signals
Indicator
IMNM
AMC
Relative Strength Index (RSI) 35.85 50.98
Support Level $23.67 $2.32
Resistance Level $25.07 $3.00
Average True Range (ATR) 1.00 0.15
MACD -0.59 -0.02
Stochastic Oscillator 6.86 40.91

Price Performance

Historical Comparison
IMNM
AMC

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About AMC AMC Entertainment Holdings Inc.

AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.

Share on Social Networks: